Peptide Profile
Cerluten
Brain-derived peptide bioregulator complex containing AED, KED, AEDG, and KE peptides that promote neurogenesis through histone binding, restore dendritic spine architecture under neurotoxic conditions, and enhance cognitive recovery in stroke and brain injury patients
Dose Range
10-20mg
Frequency
Once daily
Route
Oral (capsule)
Cycle Length
8-12 weeks
Onset
Gradual (3-4 weeks)
Evidence
Limited
Compound Profile
Scientific & Efficacy Data
C11H17N3O8 (representative primary component)
Molecular Formula
319.3 g/mol (representative; complex contains peptides from 200-500 Da)
Molecular Weight
Short plasma half-life for individual peptide components (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to gene expression
Half-Life
Oral and sublingual absorption via intestinal peptide transporters (PepT1); component peptides cross the blood-brain barrier; sublingual form bypasses first-pass hepatic metabolism
Bioavailability
75007-24-8
CAS #
194641
PubChem ID ↗
Developed By · 1990s-2000s (based on brain peptide extract research beginning in the 1980s)
Academic research consortium
Multiple research institutions
Primary Benefits
Amino Acid Sequence
Sequence not publicly available or proprietaryDosing
How much
do I take?
Starting Dose
1 capsule (10-20 mg) once daily OR 5-6 sublingual drops 3 times daily
Begin with the standard starting protocol. Capsules are taken before breakfast with water. Sublingual drops (0.25-0.35 mL per dose) are held under the tongue for 1-2 minutes before swallowing, 10-15 minutes before eating. The sublingual form provides faster absorption and bypasses first-pass metabolism. Effects are gradual — allow the full initial period before assessing response.
Standard Dose
1-2 capsules daily OR 5-6 drops 3-4 times daily
Standard clinical protocol for cognitive support and post-stroke recovery. In Russian clinical studies, 1-2 capsules were given 2-3 times daily for 10-20 days with significant EEG and cognitive improvements. Repeat courses every 3-6 months. Can be combined with Pinealon for serotonin/melatonin support or Epithalon for neuroendocrine support. Track cognitive changes using standardized assessments if possible.
Advanced Dose
2 capsules 2-3 times daily
Clinical trial protocol used in the 48-patient CNS disease study at the Saint Petersburg Institute. This higher-frequency regimen produced significant improvements (64.6% of patients) and EEG normalization. Typically reserved for structured clinical protocols under medical supervision. Often combined with other Khavinson bioregulators: Endoluten for neuroendocrine support, Vladonix for immune function, Sigumir for musculoskeletal, Svetinorm for liver, and Ventfort for vasculature.
Timing
Best time to take
Take Cerluten at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
With food?
Cerluten can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
If stacking
Cerluten should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Suitability
Is this
right for me?
Best For
Cognitive recovery following stroke or traumatic brain injury
Cerluten is particularly well-suited for individuals focused on cognitive recovery following stroke or traumatic brain injury. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Neuroprotection against age-related cognitive decline and neurodegeneration
Cerluten is particularly well-suited for individuals focused on neuroprotection against age-related cognitive decline and neurodegeneration. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting neurogenesis and neuronal repair in aging brain tissue
Cerluten is particularly well-suited for individuals focused on supporting neurogenesis and neuronal repair in aging brain tissue. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive bioregulatory approach to brain aging using multiple complementary peptide components
Cerluten is particularly well-suited for individuals focused on comprehensive bioregulatory approach to brain aging using multiple complementary peptide components. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider Alternatives If
Who Should Avoid
Do not use if
- ×Known hypersensitivity to peptide bioregulators or bovine-derived products
- ×Pregnancy and breastfeeding — insufficient reproductive safety data
- ×Active CNS infection — treat infection before initiating peptide bioregulator therapy
- ×Prion disease concerns — although manufacturing processes include purification to remove proteins > 5 kDa, individuals with heightened prion risk should exercise caution
Use with caution if
- !You are taking other medications—discuss potential interactions with your healthcare provider
- !You have a history of liver or kidney disease
- !You are elderly or have multiple medical conditions
- !You are planning surgery in the near future—inform your surgeon about Cerluten use
- !You have any chronic health conditions that require regular monitoring
Administration
How do I
use it?
Reconstitution
What you need
- •Cerluten in its prescribed form
- •Clean, dry storage container
- •Measuring device if applicable (oral syringe, measuring cup)
- •Calendar or reminder app for dosing schedule
Injection
Route
Cerluten is administered Oral (capsule)—no injection required
Best sites
- •Not applicable—this is not an injectable formulation
Technique
- 1.Follow the specific administration instructions for your Cerluten formulation
- 2.Take or apply as directed by your healthcare provider
- 3.Store properly between uses according to package instructions
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
Cerluten is a peptide extract from cerebral tissue of young animals that is not FDA-approved and lacks rigorous clinical safety data. As an undefined mixture of peptides and proteins from animal sources, quality control and batch consistency cannot be guaranteed. Potential risks include allergic reactions to animal-derived proteins, contamination with microbial pathogens or prions, and unknown long-term immunological effects. No comprehensive safety studies have been conducted in humans, and the active pharmaceutical components have never been identified or standardized. The product exists primarily in Russian and Eastern European medical markets without Western regulatory oversight.
Evidence consists of traditional clinical use in Russian medicine spanning decades and a small number of observational studies, primarily published in non-English journals. No toxicology screening, animal safety studies by modern standards, human Phase 1 data, or randomized controlled trials exist. Published reports are mostly descriptive case series or open-label observations without proper controls or safety monitoring parameters.
Common Side Effects
Experienced by some users
Mild headache
Transient headache during the initial days of treatment as brain neurochemistry adjusts to enhanced neuronal gene expression and modified signaling patterns.
Management: Ensure adequate hydration. Usually self-limiting within 3-5 days. Reduce dose temporarily if persistent.
Mild drowsiness
Slight fatigue or drowsiness in the first few days, particularly with the sublingual form, as neuronal activity patterns shift.
Management: Take in the morning or early afternoon. Usually resolves within the first week of use.
Mild GI discomfort
Slight nausea or stomach discomfort with oral capsule administration, common with peptide supplements.
Management: Take capsules with a small amount of food or water. Consider the sublingual form to bypass the GI tract.
Vivid dreams
Enhanced dream vividness reflecting active neuroplasticity and neural reorganization processes stimulated by the peptide complex.
Management: Generally benign and may indicate active neurogenesis. No action typically required.
Less Common
- •Transient sleep pattern changes
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Cerluten
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Cerluten should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
With medications
- !Other CNS-active peptide complexes at high doses without medical guidance — potential for overlapping epigenetic effects - Use with caution—discuss with your healthcare provider.
- !Strong sedatives or CNS depressants — may produce additive sedation - Use with caution—discuss with your healthcare provider.
- !Immunosuppressive medications — Cerluten's component peptides have immunomodulatory properties that may interact with immunosuppression - Use with caution—discuss with your healthcare provider.
With supplements
- ✓Multivitamins - Generally safe to take alongside Cerluten. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
Does it
work?
Evidence Level
Limited human trials
What to Expect
Days 1-10
What you might notice
- •Subtle initial changes — possibly slightly improved mental clarity or mood stability
- •Mild side effects (headache, drowsiness) that resolve within the first few days
- •Vivid dreams indicating early neural reorganization
- •No dramatic cognitive changes expected yet — epigenetic mechanisms are building
What's normal
- •Effects are subtle initially — the multi-peptide complex is working at the epigenetic level to alter gene expression through histone binding and DNA interaction
- •Component peptides are beginning to upregulate neurogenic markers (nestin, GAP43) and anti-aging genes (SIRT-6, IGF1)
- •Clinical studies showed EEG changes developing within the 10-20 day treatment period
What's next
- →Continue the full treatment course — clinical benefits were observed at 10-20 days in studies
- →Track any changes in memory, attention, or mental capacity for comparison
- →The histone-peptide interactions initiated now will produce cumulative protein synthesis changes
Week 2-4
What you might notice
- •Improved mental capacity and ability to focus on complex tasks
- •Better memory function — both formation of new memories and recall of existing ones
- •Enhanced attention span and reduced mental fatigue
- •In post-stroke patients: measurable improvements in neurological function and MMSE scores
- •Greater cognitive resilience under stress or demanding conditions
What's normal
- •This is the therapeutic window where clinical studies demonstrated significant EEG normalization
- •64.6% of patients in the 48-patient study showed significant improvement in this timeframe
- •Neurogenic markers (nestin, GAP43, doublecortin) should be upregulated, supporting new neuronal development
- •Dendritic spine preservation mechanisms (EDR component) are actively protecting synaptic architecture
What's next
- →Complete the full course duration (20-30 days for standard; 10-20 days for clinical protocol)
- →Benefits will continue to develop after the course ends as structural neuroplastic changes mature
- →Plan the next course in 3-6 months to reinforce and build upon the neurological improvements
Month 1-6 (inter-course period)
What you might notice
- •Sustained cognitive improvements from persistent epigenetic changes and structural neuroplasticity
- •Ongoing neuroprotective benefits from upregulated SIRT-6 and antioxidant pathways
- •Neurogenesis-driven improvements may continue developing for weeks after the active course
- •Benefits may gradually diminish over 3-6 months, indicating readiness for the next treatment course
What's normal
- •Epigenetic modifications and structural neuronal changes persist beyond the active treatment period
- •Khavinson bioregulator protocols are designed as cyclical treatments with 3-6 month intervals
- •Long-term clinical follow-up (1-10 years) has shown sustained neurological benefits with repeated courses
- •Each subsequent course reinforces and extends the benefits from previous treatments
What's next
- →Begin the next Cerluten course after 3-6 months for sustained neurocognitive benefits
- →Consider combining with complementary bioregulators: Pinealon for serotonin, Epithalon for melatonin
- →Khavinson recommends a comprehensive 6-bioregulator protocol twice yearly for optimal anti-aging support
Signs It's Working
Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Cerluten over time
- ✓Reduction in symptom frequency or severity
General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not Seeing Results?
Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key Research
"Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer's Disease"
Ilina A, Khavinson V, Linkova N, 2022
Finding: Cerluten's short peptides work like molecular switches that control which genes your brain cells turn on and off, acting directly on the proteins that package your DNA. This epigenetic control is crucial because it allows damaged brain cells to reboot their protective and regenerative programs, offering hope for treating Alzheimer's disease.
View Study"AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism"
Khavinson V, Diomede F, Mironova E, 2020
Finding: When human stem cells were exposed to the AEDG peptide from Cerluten, their brain-cell markers increased by 1.6 to 1.8 times, including growth-associated proteins critical for forming new neurons. The peptide worked by binding directly to the DNA-packaging proteins, showing that Cerluten acts at the fundamental genetic level to reprogram cells toward brain repair.
View Study"Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease"
Kraskovskaya NA, Kukanova EO, Lin'kova NS, 2017
Finding: When Cerluten peptides were added to simulated Alzheimer's damage in the lab, one peptide restored 71% of the nerve cell connection points that had been destroyed, while another restored 20%. These connection points are where memory and thinking happen, so rebuilding them is like rewiring broken circuits in a damaged brain.
View Study"Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides"
Ashapkin V, Khavinson V, Shilovsky G, 2020
Finding: A key Cerluten peptide turned on growth factors in aging cells by 3.5 to 5.6 times, activating genes linked to longevity and turning down genes that signal aging. This molecular dial-turning suggests Cerluten can reverse aging processes in brain stem cells at incredibly tiny doses.
View Study"Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro"
Lin'kova NS, Drobintseva AO, Orlova OA, 2016
Finding: Every peptide in Cerluten blocked a destructive enzyme (MMP-9) that tears apart cellular machinery as we age, while boosting two key regeneration markers. Some peptides also shut down cellular death pathways, meaning Cerluten works like a multi-tool protecting aging cells from multiple directions.
View StudyFrequently Asked Questions